BIAF Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.1M
-29.1%
1.5M
+11.8%
1.4M
-15.1%
1.6M
+10.1%
1.4M
Cost of Revenue
0
0
0
-100.0%
900.1K
0
Gross Profit
1.1M
-29.1%
1.5M
+11.8%
1.4M
+95.1%
692.7K
-52.1%
1.4M
Operating Expenses
4.6M
-5.5%
4.8M
-2.5%
5.0M
+29.7%
3.8M
+2.4%
3.7M
R&D
640.2K
-23.6%
837.5K
+22.5%
683.7K
+2.2%
668.8K
+41.1%
473.9K
SG&A
2.8M
-3.5%
2.9M
-11.8%
3.2M
+6.7%
3.0M
+37.5%
2.2M
Operating Income
-3510672
-5.3%
-3334864
+7.8%
-3616976
-15.3%
-3136963
-36.8%
-2292846
EBITDA
-3443830
-5.2%
-3273308
+6.5%
-3502458
-16.2%
-3013304
-38.3%
-2179486
Net Income
-5277023
-56.8%
-3366082
+7.3%
-3630610
-15.7%
-3137466
+37.9%
-5051084
EPS (Basic)
$-5.89
+38.6%
$-9.60
+21.0%
$-12.15
—
$-71.05
EPS (Diluted)
$-5.89
+38.6%
$-9.60
+21.0%
$-12.15
—
$-71.05
Shares (Diluted)
896.3K
+157.2%
348.5K
+16.3%
299.7K
—
71.1K
bioAffinity Technologies (BIAF) — Financials